Nanaomycin is a polyketide antibiotic produced by the bacterium Streptomyces rosa. It is a potent inhibitor of bacterial DNA gyrase, an enzyme essential for bacterial DNA replication. Nanaomycin has demonstrated antibacterial activity against a broad spectrum of bacteria, including Gram-positive, Gram-negative, and Mycobacterium species. Its unique structure and mechanism of action have made it a target of interest for research and development of novel antibacterial agents. Research on Nanaomycin includes studying its biosynthesis, its effects on bacterial growth and DNA replication, and its potential for use in drug development. It is also being investigated for its anti-cancer properties and its potential to overcome antibiotic resistance.'
| ID Source | ID |
|---|---|
| PubMed CID | 40586 |
| CHEMBL ID | 1212972 |
| CHEBI ID | 193279 |
| SCHEMBL ID | 18567076 |
| Synonym |
|---|
| smr001565684 |
| NEURO_000132 |
| CHEMBL1212972 |
| NSC267461 , |
| mls002702116 , |
| nanaomycin |
| nsc-267461 |
| 2-(9-hydroxy-1-methyl-5,10-dioxo-3,4-dihydro-1h-benzo[g]isochromen-3-yl)acetic acid |
| (9-hydroxy-1-methyl-5,10-dioxo-3,4,5,10-tetrahydro-1h-benzo[g]isochromen-3-yl)acetic acid |
| NCI60_002162 |
| SMP2_000265 |
| CHEBI:193279 |
| BRD-A86160188-001-01-8 |
| ZCJHPTKRISJQTN-UHFFFAOYSA-N |
| 2-[1-methyl-9-oxidanyl-5,10-bis(oxidanylidene)-3,4-dihydro-1h-benzo[g]isochromen-3-yl]ethanoic acid |
| 2-(9-hydroxy-5,10-diketo-1-methyl-3,4-dihydro-1h-benz[g]isochromen-3-yl)acetic acid |
| bdbm80078 |
| 2-(9-hydroxy-1-methyl-5,10-dioxo-3,4-dihydro-1h-benzo[g][2]benzopyran-3-yl)acetic acid |
| cid_40586 |
| SCHEMBL18567076 |
| DTXSID70866291 |
| (9-hydroxy-1-methyl-5,10-dioxo-3,4,5,10-tetrahydro-1h-naphtho[2,3-c]pyran-3-yl)acetic acid |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dose-response experiments in primary cells confirmed pathway selectivity, but importantly also revealed differential inhibition of cell types and new druggability trends across multiple compounds." | ( High-content single-cell drug screening with phosphospecific flow cytometry. Clutter, MR; Crane, JM; Krutzik, PO; Nolan, GP, 2008) | 0.35 |
| Class | Description |
|---|---|
| benzoisochromanequinone | A class of Streptomyces aromatic polyketide antibiotics. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 56.2341 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 0.8913 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| WRN | Homo sapiens (human) | Potency | 11.2202 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.0842 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 0.8913 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 2.8184 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| 67.9K protein | Vaccinia virus | Potency | 1.7039 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| IDH1 | Homo sapiens (human) | Potency | 1.2995 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 10.0000 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 3.5481 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 2.3778 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 3.1623 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 0.5255 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Vpr | Human immunodeficiency virus 1 | Potency | 1.5849 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 31.6228 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 0.3548 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 5.9622 | 1.9953 | 25.5327 | 50.1187 | AID624287; AID624288 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 0.6310 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 89.1251 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, RNA-directed RNA polymerase NS5 | Dengue virus 2 16681-PDK53 | IC50 (µMol) | 5.0400 | 2.3700 | 54.1398 | 100.0000 | AID588689 |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 3.2300 | 0.6902 | 0.8145 | 0.9388 | AID652153 |
| C-C chemokine receptor type 6 | Homo sapiens (human) | IC50 (µMol) | 66.6000 | 11.5000 | 14.3000 | 17.1000 | AID504728 |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 76.4200 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
| Vif | Human immunodeficiency virus 1 | IC50 (µMol) | 4.1600 | 0.2700 | 34.0015 | 100.0000 | AID1117319 |
| Tat | Human immunodeficiency virus 1 | IC50 (µMol) | 100.0000 | 0.9960 | 39.8009 | 100.0000 | AID1117361 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 4.1600 | 0.2700 | 26.3638 | 100.0000 | AID1117319 |
| putative polyprotein | IC50 (µMol) | 8.9835 | 0.2508 | 3.8283 | 8.4620 | AID720577; AID720578 | |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PAX8 | Homo sapiens (human) | AC50 | 0.4690 | 0.0488 | 5.4354 | 69.1700 | AID687027 |
| aryl hydrocarbon receptor nuclear translocator | Homo sapiens (human) | AC50 | 46.9300 | 0.1900 | 23.3694 | 115.5100 | AID651703 |
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | AC50 | 0.2620 | 0.1950 | 3.6679 | 18.6960 | AID540270 |
| transforming acidic coiled-coil-containing protein 3 | Homo sapiens (human) | AC50 | 46.9300 | 0.1900 | 24.2333 | 115.5100 | AID651703 |
| heat shock protein 90, putative | Plasmodium falciparum 3D7 | AC50 | 0.1950 | 0.1950 | 4.9920 | 98.5000 | AID540268 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID495066 | Inhibition of anisomycin-induced p38 phosphorylation in human U937 cells by Phospho-Flow cytometry at 20 uM | 2008 | Nature chemical biology, Feb, Volume: 4, Issue:2 | High-content single-cell drug screening with phosphospecific flow cytometry. |
| AID495065 | Inhibition of JAK-mediated interferon-gamma-induced Stat1 phosphorylation in human U937 cells by Phospho-Flow cytometry at 20 uM | 2008 | Nature chemical biology, Feb, Volume: 4, Issue:2 | High-content single-cell drug screening with phosphospecific flow cytometry. |
| AID495064 | Inhibition of JAK-mediated GM-CSF-induced Stat5 phosphorylation in human U937 cells by Phospho-Flow cytometry at 20 uM | 2008 | Nature chemical biology, Feb, Volume: 4, Issue:2 | High-content single-cell drug screening with phosphospecific flow cytometry. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.83) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||